Abstract: Methods of treating diseases and conditions wherein an improvement in cardiac output, organ perfusion, or tissue oxygenation are disclosed. The methods include treatments of diseases and conditions, such as hypovolemic shock, with an a2 adrenergic agent, like centhaquin and centhaquin citrate. The method utilizes an a2 adrenergic agent administered at low doses with a low volume of resuscitation fluid. Purified centhaquin and centhaquin citrate also are disclosed.

Abstract: The present disclosure is related to methods and compositions for treating or preventing kidney injury or failure, comprising administering an endothelin B (ETB) receptor agonist and/or an ?2 adrenergic agent.

Abstract: A novel chemical moiety triterpenoid AECHL-1 isolated from root bark of Ailanthus excelsa having the structure:

Abstract: A novel chemical moiety triterpenoid AECHL-1 isolated from root bark of Ailanthus excelsa having anti-cancer properties exhibiting remarkable activity in treatment of various forms of tumors with specificity wherein it blocks the growth of four tumor cell lines with distinct origins and of different p53 status (B16F10 mouse melanoma, PC3 human prostate cancer, MCF-7 and MDA-MB-231 human breast cancer), having following characteristic IR, NMR and mass spectra IR (KBr): 3425, 3419 (hydroxyl group), 2972, 2966, 2923, 2873 (alkyl C—H stretch), 1733 (? lactone), 1718 (Bi acetyl), 1680 (C?O conjugation with alkene), 1652 (—C?C stretching), 1600 (aromatic), 1492, 1454, 1394 (methyl stretching), 1222 (? lactone), 1184, 1110, 1051, 1031 (acetals), 1018 nm (alkanes). 1H-NMR (DMSO, 400 Hz) ?: 0.95 (3H, t, 4?-CH3), ?:1.15 (3H, d, H-24), ?:1.235 (3H, d, 5?-CH3), ?: 1.5 (2H, ddd, 5?-CH2), ?: 1.73 (3H, ddd, H-21), ?: 1.83 (1H, s, H-9), ?: 1.87 (1H, s, H-14), ?: 1.9 (2H, s, H-18), ?: 2.16 (3H, s, H-18), ?: 2.